Relay Therapeutics (RLAY) shares surged nearly 8% on Wednesday following the announcement of promising Phase 2 results for its investigational drug, zovegalisib, which treats vascular anomalies. The positive momentum was bolstered by two analysts raising their price targets significantly—Barclays’ Peter Lawson to $27 from $21 and Citizens JMP’s Silvan Turkcan to $21 from $19—both maintaining a buy rating on the stock. The trial results indicated a 60% response rate among patients at the 12-week mark, outperforming analyst expectations and demonstrating a favorable safety profile.
Despite the enthusiasm, Relay also disclosed plans for a secondary stock offering that could exceed $200 million, which may lead to some investor concerns about dilution. However, given the company’s robust market cap of nearly $2.5 billion, the impact may be limited.
For market professionals, the key takeaway is that Relay’s strong clinical results and analyst support position it as a compelling investment in the biotech sector, even amidst potential dilution concerns.
Source: fool.com